Introduction
Efavirenz is an antiretroviral drug (ARV) that is commonly used in a highly active antiretroviral regimen for the treatment of human immunodeficiency syndrome type 1 (HIV-1) infection. It is categorically prescribed at a fixed dose of 600 mg once daily. 1) However, the prevalence of adverse drug reactions (ADR), including many central nervous system (CNS) side effects, associated with the use of efavirenz in HIV-1 infected patients is commonly reported. [2] [3] [4] Currently, the mechanism accountable for CNS toxicities associated with efavirenz remains unclear. Nevertheless, many studies have concluded the high inter-individual variability of efavirenz plasma levels in HIV-1 patients affects the accomplishment of a long-term benefit with efavirenz treatment. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] HIV-1 patients who receive the efavirenz regimen and have plasma efavirenz concentrations of <1.000 mg/L seem to have a higher risk for virological failure and an emergence of selective drug resistance, while patients with efavirenz concentration above 4.000 mg/L appear to experience many neurological adverse effects. 2, 9, 15) In this context, polymorphisms in cytochrome P450 2B6 (CYP2B6) may have major implications, both for the efficacy and the toxicity of efavirenz.
CYP2B6 is the major enzyme that is responsible for the metabolism and clearance of efavirenz.
10) The CYP2B6 gene has several polymorphisms and this may influence the isoenzyme activity. Studies have shown a significant allelic variant (the CYP2B6 c.516G>T polymorphism) which may decrease the clearance of efavirenz by reducing the activity of CYP2B6 enzyme, thereby increasing the efavirenz plasma concentration to levels that may lead to CNS toxicities.
9) The effect of genetic polymorphisms on efavirenz pharmacokinetics receives much attention because the plasma concentrations of efavirenz were found to be a predictor of treatment success and the risk of ADRs including headache, dizziness and insomnia. [2] [3] [4] 9) Intolerance and ADRs are the main factors behind the discontinuation of many ARVs. Treatment failures, poor adherence and compliance, and long-term adverse drug reactions are limitations of current antiretroviral therapy. 1, 17, 18) According to Thailand's guideline, a patient would typically have been offered a non-nucleoside reverse transcriptase inhibitor-based regimen as his/her firstline regimen, when emergence of resistance to efavirenz and/or nevirapine therapy was documented. [19] [20] [21] [22] [23] [24] [25] However, the high discontinuation rate of efavirenz can also be due to the severity or the persistence of CNS toxicities. 17, 18) Therefore, avoidance of drug toxicity should be factored in to the future strategic approach in the management of HIV infection.
The aim of this study was to examine the frequencies of six CYP2B6 polymorphisms (c.64C>T, c.499C>G, c.516G>T, c.785A>G, c.1375A>G and c.1459C>T) and the impact of these polymorphisms on efavirenz plasma concentrations in 100 Thai HIV-1 infections. Additionally, we also investigated the association of CYP2B6 polymorphisms and haplotypes with efavirenz plasma concentrations.
Methods
Sample populations and characteristics: One hundred Thai adults with HIV-1 infection were recruited at Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand. Enrolled patients were aged ²18 years, had no opportunistic infection and were taking an antiretroviral regimen with tenofovir (300 mg), lamivudine (300 mg) and efavirenz (600 mg) at bed time. The mid-dose efavirenz plasma concentration was determined at 12 weeks following the initiation of antiretroviral therapy. Patients receiving concomitant treatments that could potentially affect efavirenz pharmacokinetics were excluded. All subjects provided written informed consent within the cohort study, which included the use of stored samples for future research following specific ethical clearance. This study was approved by the Ethics Committee of the Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand.
CYP2B6 genotyping: A total of six SNPs within CYP2B6 were genotyped (GenBank accession number NG_000008.7). SNPs c.516G>T (rs3745274) and c.785A>G (rs2279343) have previously been reported to influence enzyme activity and efavirenz concentrations. 9, 10) The c.499C>G (rs3826711) SNP, part of the *26 allele, was associated with high efavirenz plasma concentrations in Japanese subjects, and three other SNPs also assessed in this study, c.64C>T (rs8192709), c.1375A>G (rs3211369), and c.1459C>T (rs3211371) were also selected for assessment. 9, 10) Pre-designed TaqMan assays (Applied Biosystems, Foster City, CA), were used to genotype the CYP2B6 c.516G>T (assay ID C -7817765_60), c.64C>T (assay ID C -2818162_20), c.499C>G (assay ID C -2752377_10), c.1375A>G (assay ID C -2741754_10), c.1459C>T (assay ID C -30634242_40), g.3003T>C (assay ID C -2818167_10) and g.21563C>T (assay ID C -22275631_10). The CYP2B6 c.785A>G were performed by custom TaqMan assays (Applied Biosystems). The sequences of primers and probes were: CYP2B6 c.785A>G, TGGAGAAG-CACCGTGAAACC (forward), TGGAGCAGGTAGGTGTCGAT (reverse), VIC-CCCCCAAGGACCTC-MGB (wild-type), FAM-CCCCAGGGACCTC-MGB (mutant).
For SNP analysis, these 6 SNPs were genotyped using allelespecific fluorogenic 5A nuclease chain reaction assay with predesigned primers and TaqMan MGB probes (TaqMan SNP Genotyping Assay; Applied Biosystems). Sequence-specific forward and reverse primers to amplify the polymorphic sequence of interest used two TaqMan MGB probes: one probe was labeled with VIC dye and detected the Allele 1 sequence; the second probe was labeled with FAM dye and detected the Allele 2 sequence.
Measurement of efavirenz plasma concentrations: Fasting plasma efavirenz level at 12 h after dosing was measured using a validated high performance liquid chromatopraphy assay at 12 weeks after ART initiation. Briefly, patient plasma samples (300 µL) and all calibration and control samples were heat inactivated in a water bath at 56°C for 30 min prior to assay. Sample pretreatment involved protein precipitation with acetonitrile (360 µL) and following centrifugation the sample supernatant was injected into the HPLC machine.
Analysis was performed using an Agilent 1100 HPLC machine with an Omnispher C18 (150 © 4.6 mm I.D./particle size 5 µm) analytical column (Varian, CA), a Chromquard RP guard column and a mobile phase consisting of 10 mM KH 2 PO 4 pH 3.1 -acetonitrile (50:50, v/v). The retention time for efavirenz was 5.1 min. The peak of this compound was well resolved and free of interference from endogenous compounds in the plasma. The lower limit of quantification (LLOQ) of efavirenz is 0.2 mg/L. The detection limit was defined as a signal-to-noise ratio of 3:1. The calibration standards for plasma samples were linear in the range of 0.2-20 mg/L. Low, medium and high level QC samples were prepared at 0.4, 1.5 and 10 mg/L, respectively. The intra-and interday precision was within 0.0758% and 0.0091%, respectively. The assay accuracy was 93-104%. This assay was developed at the Department of Clinical Pharmacology at the University Medical Centre Nijmegen, The Netherlands. The sample peak heights were processed by ChromQuest Software version 4.1.
Statistical analyses: CYP2B6 haplotype determination was interpreted using The Human Cytochrome P450 (CYP) Allele Nomenclature Database (http://www.cypalleles.ki.se/cyp2b6.htm). All genotype distributions were tested for Hardy-Weinberg equilibrium using exact tests. SNPs with a call rate <95% were omitted. A Kruskal-Wallis test was used to test for significant difference in efavirenz concentrations between genotypes. Mann-Whitney U tests were used to compare efavirenz concentrations between two genotypes. The QTLHAPLO program was used to identify the association between the CYP2B6 haplotypes and the efavirenz plasma concentration. Statistical significance was defined as p < 0.05.
Results
Study population and clinical data: In this study, a total of 100 HIV-1 infected patients were recruited. All patients were started on a once-daily antiretroviral regimen of 300 mg tenofovir, 300 mg lamivudine and 600 mg efavirenz at bed time. The demographic and clinical data of the participants are shown in Table 1 . The predominant population was female (75.0%). The median (interquartile range: IQR) plasma HIV RNA was 6.80 (1.06-9.36) log copies/mL and median (IQR) CD4 cell count was 47.50 (17- Table 2 .
CYP2B6 polymorphisms are correlated with efavirenz plasma concentrations: In the entire cohort study, 3 out of 6 SNPs (c.64C>T, c.516G>T and c.785A>G) showed statistically significant difference in efavirenz plasma concentrations between genotype groups (p < 0. Frequencies of CYP2B6 haplotypes in Thai HIV-1 infected patients: The most frequent CYP2B6 alleles in the population tested here were *1 (117/200; 58.5%), and *6 (63/200; 31.5%), whereas only two *5 alleles were identified (1.0%). According to the haplotype, the most frequent haplotypic combinations were *1/*6, *1/*1, *1/*2 and *6/*6 at the frequencies of 42.0%, 32.0%, 8.0% and 7.0%, respectively.
No CYP2B6 polymorphism was detected in 32 patients and their haplotypes were determined to be *1/*1. The haplotypes of single-SNP carriers with c.64CT, c.516GT, c.785AG and c.1459CT were determined to be *1/*2 (n = 8), *1/*6 (n = 42), *1/*4 (n = 3), and *1/*5 (n = 0), respectively, whereas those of homozygous carriers with both c.516TT and c.785GG were determined to be *6/*6 (n = 7). Two patients with c.64CT, c.516GT, and c.785AG was identified as *2/*6, while 3 patients carrying both c.516GT and c.785GG genotypes but no other polymorphisms, were determined to be *4/*6 ( Table 3) .
Relationship between CYP2B6 haplotype and efavirenz plasma concentrations: The results of CYP2B6 haplotype association with efavirenz plasma concentrations are summarized in Figure 2 . Among the subjects, the median plasma efavirenz concentration was 2.260 mg/L (IQR, 1.442-3.665) and had a high inter-individual variability ranging from 0.58 mg/L to 23.35 mg/L. The median efavirenz level was 1.570 mg/L (IQR, 1.295-2.670) for individuals homozygous for the CYP2B6 *1/*1 (n = 32/100). From the analysis, significant elevation of efavirenz levels was found for *1/*6 (n = 42/100, p = 0.0011) and *6/*6 (n = 7/100, p < 0.00001) haplotype forms. There was no significant difference in the efavirenz levels for carriers of *1/*2, *1/*4, *2/*4, *2/*6, *4/*6 or *5/*6.
Discussion
This study identified 6 single nucleotide polymorphisms (SNPs) in the cytochrome P450 2B6 (CYP2B6) gene (SNPs: c.64C>T, c.499C>G, c.516G>T, c.785A>G, c.1375A>G and c.1459C>T) which may act as an additional independent predictor of efavirenz plasma concentrations, in addition to that provided by the wellstudied CYP2B6 c.516G>T polymorphism.
2-4,7-9) The aims of this study were to evaluate the frequencies of all 6 SNPs in Thai HIV-1 infected patients, and to investigate the association of CYP2B6 polymorphism with efavirenz plasma concentrations.
In the current study, the genetic variability of the CYP2B6 gene in Thai HIV-1 infected patients was performed using TaqMan genotyping assay for a total of 100 individuals compared with previous studies. 7) Among them, the most frequent SNPs in this study were c.785A>G (63%) and c.516G>T (56%). The result showed that CYP2B6 frequencies in this study were not significantly different to others reported. [7] [8] [9] From the cases observed, we found that CYP2B6 c.499C>G and c.1375A>G polymorphism was entirely absent in our cohort, whereas a low frequency of this SNP was reported in a Japanese population. 11) In addition, the relationships between CYP2B6 haplotypes and efavirenz plasma concentrations were examined in 100 patients, who received a standard dose of efavirenz during the study. For SNPs c.516G>T and c.785A>G, homozygous variants had higher level of efavirenz plasma concentrations than the recommended optimized range (4 mg/L) 11, 15, 26, 27) and were equal to subjects with heterozygous variants and homozygous wild-type cohorts. Many studies have shown strong correlation between CYP2B6 c.516G>T polymorphism and a higher efavirenz plasma concentration than the optimal therapeutic concentration (>4,000 µg/mL), which may result in CNS toxicity. 2, 9, 15) Our results are in accord with previous studies. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] CYP2B6 c.516G>T had a significant association with a high efavirenz plasma level including SNP c.785A>G. These polymorphisms were commonly found in the Thai population, which may explain the finding of higher plasma efavirenz concentrations in the Thai HIV-1 infected patients. 7, 8, 28) Since only one patient had CYP2B6 c.64TT, it was not possible to establish a relationship between this polymorphism and the efavirenz level in this population.
Five alleles (*1, *2, *4, *5, and *6) were found in our population. CYP2B6*6, which has two coding mutations, was the most frequent variant allele in this population. Haplotype frequencies were similar to those published previously. 29) Genetic interaction of various metabolic genes identified that allele *6 is the best predictor of high efavirenz plasma concentrations. 11, [13] [14] [15] [16] Our results also confirm previous studies that CYP2B6*6/*6 was strongly associated with efavirenz plasma levels that are above the therapeutic range. The exact effects of CYP2B6 genetic polymorphisms on enzyme activity have not yet been fully established. It has been previously reported, however. 
CYP2B6 Polymorphisms and Efavirenz Levels in Thai Patients
This study had some limitations. First, other CYP2B6 genetic variations associated with plasma efavirenz level were not investigated in this study, including CYP2B6 983T>C, for example. CYP2B6 983T>C has been associated with plasma concentrations of efavirenz in Africans and Blacks 30, 31) ; however, it was absent in Asians. 30, 32) Second, alternative pathways of efavirenz metabolism via CYP2A6 in patients with impaired CYP2B6 function have been reported. 33 ) CYP3A4*1B was associated with lower efavirenz clearance. Neither CYP3A4/5 nor CYP2A6 SNPs were examined in this study; however, they were shown to be weakly associated with efavirenz levels and their variants. 4, 14, 34, 35) More recently, UDPglucuronosyltransferase 2B7 (UGT2B7) has also been reported to be associated with efavirenz metabolism; its role as an indicator of clinical outcomes needs to be defined in Thai populations, however. 36) In conclusion, our study has shown that a polymorphism in the CYP2B6 gene is associated with higher plasma efavirenz concentrations. The presence of CYP2B6 polymorphisms may have a predictive value over an efavirenz concentration that can lead to a significant risk of adverse drug reaction (ADR), and in particular CNS toxicity, in Thai HIV-1 patients. Since genotyping has not been established in routine clinical practice, clinicians can initially be guided by the phenotype assessed through the plasma efavirenz concentrations. [37] [38] [39] Moreover, the therapeutic drug monitoring for the optimization and individualization of efavirenz administration is important in the treatment of HIV-1 infections.
